SOURCE: Transdel Pharmaceuticals

December 10, 2007 09:01 ET

Transdel Pharmaceuticals to Present at the New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference

LA JOLLA, CA--(Marketwire - December 10, 2007) - Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications, today announced that Dr. Juliet Singh, President and Chief Executive Officer, will present a company overview at the New York Society of Security Analysts ("NYSSA") 11th Annual Biotech & Specialty Pharma Industry Conference on Wednesday, December 12th at 2:05 p.m. Eastern Time. The conference will be held at NYSSA's headquarters located at 1177 Avenue of the Americas in New York City.

In addition, Dr. Singh stated, "The entire management team is pleased to be on schedule with our strategic plan of filing for Ketotransdel™ Phase 3 clinical trials with the FDA and the development of our pipeline." Dr. Singh continued, "We are well positioned to advance the development of Ketotransdel™. Also, we are continuing our discussions with ideal commercial partners for the future commercialization of Ketotransdel™."

Furthermore, the Company recently announced that Anthony S. Thornley had been appointed to the Company's Board of Directors. Mr. Thornley currently serves on the Board of Directors at Callaway Golf Incorporated, Cavium Networks Inc. and Airvana Inc. Most recently he served as President and Chief Operating Officer of QUALCOMM, Inc., a wireless communication technology and integrated circuit company. Prior, he was with Nortel Networks, a telecommunications equipment manufacturer, for sixteen years.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel™, utilizes the Company's innovative proprietary Transdel™ cream formulation to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissues where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the Transdel™ platform technology for products in pain management and other therapeutic areas. For more information, please visit www.transdelpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contact Information

  • For further information, please contact:

    Thomas P. Walsh
    Alliance Advisors, LLC
    (212) 398-3486
    Email Contact
    Or

    John Lomoro
    CFO
    Transdel Pharmaceuticals, Inc.
    (858) 457-5300
    Email Contact